Objective To develop and assess the performance of a predictive model for the infiltration degree of solitary pulmonary pure ground-glass nodules (pGGN) using CT, blood cell parameters, and tumor markers. Methods The clinical data of patients with solitary pulmonary pGGN, collected from Tangshan Gongren Hospital between June 2021 and April 2024, were analyzed. They were divided into a training set and a test set in a 7∶3 ratio. Lasso-logistic regression was used to identify risk factors for invasive adenocarcinoma and construct the model. The model's performance was assessed using receiver operating characteristic (ROC) curves, calibration curves, mean absolute error (MAE), mean squared error (MSE), and accuracy. Results The study included 528 patients (265 males, 263 females) with a median age of 54 years (interquartile range: 45-59). Lasso-logistic regression identified increased diameter, vascular convergence sign, pleural indentation sign, elevated mean CT value, and elevated carcinoembryonic antigen levels as independent risk factors for solitary pulmonary pGGN infiltration. In contrast, a rounded or similarly rounded shape and an elevated platelet-to-lymphocyte ratio were independent protective factors (P<0.05). In the training set, the area under the ROC curve of model Z (comprising diameter, vascular convergence sign, pleural indentation sign, rounded or similarly rounded, mean CT value, carcinoembryonic antigen, and platelet-to-lymphocyte ratio) was 0.875, which was greater than that of model C (comprising diameter, vascular convergence sign, pleural indentation sign, rounded or similarly rounded, and mean CT value; 0.852) and model S (comprising carcinoembryonic antigen and platelet-to-lymphocyte ratio; 0.753). The MAE, MSE, and accuracy of model Z were 0.035, 0.003, and 0.808, respectively, which were lower than those of model C (0.058, 0.006, and 0.827) and higher than those of model S (0.031, 0.001, and 0.648). In the test set, the area under the ROC curve, MAE, MSE, and accuracy of model Z were 0.829, 0.051, 0.004, and 0.755, respectively, which were higher than those of model C (0.780, 0.038, 0.002, and 0.730) and model S (0.740, 0.042, 0.002, and 0.692). Conclusion The model constructed from diameter, vascular convergence sign, pleural indentation sign, rounded or similarly rounded shapes, mean CT value, carcinoembryonic antigen, and platelet-to-lymphocyte ratio aids in assessing the infiltration degree of pulmonary pGGN, with superior performance compared to models based solely on CT or those based on tumor markers combined with blood cell parameters.
ObjectiveTo summarize the clinical experience in the treatment of high-risk patients with severe aortic valve disease by transcatheter aortic valve implantation (TAVI) via heart apex approach and to evaluate the early efficacy.MethodFive patients who underwent TAVI via heart apex approach from September 2017 to February 2019 in Henan Thoracic Hospital were retrospectively analyzed, including 3 males and 2 females, aged 65-84 (74.6±4.5) years.ResultAll operations were performed through a small left incision into the thoracic cavity (3-5 cm), and then through the J-Valve transport system, the aortic valve was successfully released via heart apex after precise positioning under digital subtraction angiography. One patient developed ventricular fibrillation during the operation, and the operation was completed with the assistance of emergency femoral arteriovenous catheterization cardiopulmonary bypass; one patient underwent percutaneous coronary intervention first because of severe coronary stenosis; one patient had paroxysmal atrial fibrillation during the perioperative period, and had hepatorenal insufficiency and thrombocytopenia after the operation, and was improved after medical treatment; one patient had perivalvular leak during the operation, and was improved after re-implantation of the valve; one patient was in stable condition during operation and recovered smoothly after operation. Surgery was successful in all 5 patients. The follow-up time was 2-19 months, and the early clinical effect was good.ConclusionThe short-term clinical efficacy of TAVI via heart apex approach in the treatment of high-risk severe aortic valve disease is definite and safe, but the long-term and medium-term effects need to be further evaluated.